In 27-month-old mice, inducible muscle-specific deletion of Depdc5, a brake on mTORC1, produced a strong rise in inflammatory and immune-related transcripts, plus shifts in metabolic and angiogenic pathways and higher TNF-α protein. Macrophage phenotype and capillary density did not change. Dietary rapamycin partly restored mTORC1 signaling and angiogenesis-related transcripts but left the inflammatory transcripts and TNF-α untouched. All evidence comes from mice, not humans.
The result sharpens a central question in geroscience: rapamycin extends lifespan in rodents, yet this work suggests it may not fix every downstream consequence of excess mTORC1 activity. Chronic activation alone was enough to deepen the low-grade inflammation that already accompanies aging, which supports mTORC1 as a causal driver rather than a bystander. The rapamycin shortfall is the more provocative finding. It hints that inflammation may persist through rapamycin-insensitive mTORC1 outputs or through routes the drug does not reach at the dose and route used, a caveat since dietary dosing in aged animals may leave signaling only partly suppressed. Limitations are real: a single age point, transcript-level readouts, no functional strength or mass measures, and an artificial genetic model that exceeds the physiological mTORC1 rise seen in normal aging. For adults, there is no direct action here. It adds mechanistic nuance that will shape how researchers pair mTOR inhibitors with anti-inflammatory strategies, and it cautions against assuming rapamycin-like drugs will cure muscle inflammation. Incremental, but informative.
